


Innovations in Transcatheter Valvular Interventions – **What to Expect in the Next Decade?**

Leor Perl, MD

Rabin Medical Center






“Study the past if you would define
the future.”


Confucius



Epidemiological Features of Aortic Stenosis in USA



Epidemiological Features of Aortic Stenosis in France






































Figure 2 | All-cause mortality in pivotal TAVI/SAVR studies grouped by risk category.



Self-expanding valves

 Corevalve ●	 Evolut R ●●	 Evolut PRO ●●●	 Evolut PRO+ ●●	 Evolut FX ●●	 Acurate TA ●	 Acurate Neo ●	 Acurate Neo 2 ●	 Portico ●●	 Navitor ●●	 Hydra ●
 Allegra ●	 JenaValve ●	 Trilogy ●	 J-Valve ●	 Venus-A ●	 Venus-A-Plus ●	 Venus-A-Pro ●	 Venus-PowerX ●	 VitaFlow ●	 TaurusOne ●	 Vienna ●


Balloon-expandable valves

 Cribier-Edwards ●	 Sapien ●	 Sapien XT ●	 Sapien 3 ●●●	 Sapien 3 Ultra ●●	 Sapien 3 Ultra Resilia ●●	 Sapien X4 ●	 MyVal ●	 MyVal Octacor ●	 DurAVR ●
--	---	--	---	---	--	--	--	--	---


Mechanically-expandable valves

 Lotus ●	 Lotus Edge ●
--	---

● Food and Drug Administration approved
 ● Certificat de Conformité Européen
 ● National Medical Products Administration of the People's Republic of China approved
 ● No longer available



The Xemed Valve




Remaining Questions for TAVR

- Very long-term durability
- Valve in valve
- HALT
- Coronary access
- How much more can we reduce side effects?

Undertreatment of Severe Mitral Regurgitation

- Mitral surgery is performed in only 15% of severe MR patients.
- 5% of secondary MR versus 29% of primary MR.






Octalina Mendoza

Mitral Transcatheter Edge-to-edge Repair



Over 100,000 procedures performed since first patient





MitraClip NTR
The original MitraClip NT size.



MitraClip XTR
Longer arms for easier grasping



Transcatheter Mitral-Valve Repair in Patients with Heart Failure



Comparison of TEER with Mitral Surgery

Population of interest

- Patients with severe mitral regurgitation seen in French hospitals 2012–2022
- Propensity matching



Intervention

Mitral transcatheter edge-to-edge repair
2160 patients




VS

Comparison

Isolated mitral surgery
2160 patients




Cardiovascular death









	Nb at Risk							
	0	0.5	1.0	1.5	2.0	2.5	3.0	3.5
Mitral surgery	2160	988	766	578	446	317	202	130
Mitral TEER	2160	1116	845	659	498	345	231	129

Clinical indications for mitral TEER.


Conventional indications



Evolving indications





One-Year Outcomes From the CLASP IID Randomized Trial for Degenerative Mitral Regurgitation



Contoured paddles


Unique central spacer






















Implant elongation



- PASCAL system is noninferior to the MitraClip system for DMR
- PASCAL system provides significant and durable MR reduction
- Marked improvements in functional class and QoL observed in both device groups


Percutaneous Mitral Valve Therapies



Direct suture annuloplasty	    
Direct ring annuloplasty	   
Coaptation enhancement	     
Valve replacement	     


MIA = minimally invasive annuloplasty; PASTA = pledget-assisted suture tricuspid annuloplasty; TRAIPTA = transatrial intrapericardial tricuspid annuloplasty.

Transcatheter Mitral Valve Replacement Systems




Transcatheter mitral valve replacement systems. (A) Tiara (Neovasc Inc.); (B) Tendyne (Abbott Vascular); (C) Caisson (LivaNova); (D) Intrepid (Medtronic); (E) CardiAQ (Edwards Lifesciences).

Transcatheter Mitral Valve Replacement Systems



Amend Valve Repair System



Coriofix




Bio ReFine

ANIMAL TRIAL RESULTS – ACUTE


sheep AS22394 - Average measurement			
Day 0			
Weight [kg]	81.4		
# of ablation points	12		
Dimensions / Average Measurements	Before	After	% (-) reduction/ (+) Increase : Nominal
C1 - C2 [cm]	4.08	3.67	-10.11%
A2-P2 [cm]	3.28	2.61	-20.2%
Annulus perimeter [cm]	12.08	10.38	-14.1%
Annulus Area [cm ²]	10.58	7.81	-26.2%
Coaptation Height [cm]	0.39	0.59	50.0%



MR PREPROCEDURE




MR POSTPROCEDURE




Remaining Questions for MR Therapy

- Competitors to TEER? TMVR Perhaps?
- Combination therapy? TEER + Annuloplasty?
- Clear clinical impact in degenerative MR vs surgery
- Optimal timing


Burden of Tricuspid Regurgitation




Tricuspid regurgitation is a public health crisis!



CENTRAL ILLUSTRATION: Transcatheter Tricuspid Valve Repair Safe and Effective in Real-World Population



Reduction in TR at 30 Days



Safety Profile at 30 Days

Major Adverse Event	Percentage
Major Adverse Event	2.7%
• Cardiovascular mortality	0.8%
• Myocardial infarction	0.0%
• Stroke	0.4%
• New onset renal failure	1.4%
• Endocarditis requiring surgery	0.0%
• Nonelective CV surgery for device-related AE	0.2%

MAEs adjudicated by independent clinical events committee




FDA Advisory Committee Votes
in Favor of Abbott's First-of-Its-
Kind TriClip™ System to Treat
People With a Leaky Tricuspid
Heart Valve




המלצות הועדה הציבורית להרחבת סל שירותי הבריאות - עדכון 2024

"תיקון דליפה טריקוספידלית קשה בחולים עם אי ספיקה לבבית ללא עדות למחלה מישראלית משמעותית, למרות מיצוי הטיפול התרופתי המקסימלי, ואשר אינם מתאימים לניתוח וקיימת בהם אנטומיית מסתם מתאימה"




Transcatheter Tricuspid Valve Therapies




TRISOLMEDICAL



















tricuspid valve replacement



TRICVALVE®



CENTRAL ILLUSTRATION: Summary of Main Outcomes at 1 Year Following TricValve

Long-Term Follow-Up of Bicaval TricValve for Severe Symptomatic Tricuspid Regurgitation, N = 44			
Findings	TRICUS Study N = 9	and	TRICUS EURO Study N = 35
Functional result	 KCCQ-12 P < 0.001 	 NYHA P < 0.001 	 6MWT P = 0.285 
Labs/Drugs	 Diuretic dose 	 NTproBNP 	 Kidney and liver function 
Prognostic result	 CV death 2.2%	 HF readmission 29.5%	 Stroke 9.0%
Safety outcomes	 Major bleeding 20.0%	 Right heart thrombi (normal leaflets) 13.6%	 TV surgery 2.2%



- TricValve CAVI associated with improved symptoms and QOL at 1 year
- Relatively low cardiac mortality

Blasco-Turrión S, et al. J Am Coll Cardiol Interv. 2024;17(1):60-72.



INNOVENTRIC

Simplicity at Heart





CONTACT



EMAIL: info@innoventric.com





ADDRESS: 3 Golda Meir, Ness-Ziona. Israel


Remaining Questions for TR Therapy


- Optimal imaging for TV
- Is T-TEER comparable to M-TEER?
- TTVR? Orthotropic?
- Clinical impact beyond quality of life
- Optimal timing

Robotic-assisted real-time MRI-guided TAVR





Robotic Aortic Valve Replacement






AI to Predict Valvular Disorders




AI to Diagnose and Characterize Valvular Disease



AI to Predict TEER Success and Guide Treatment


Severe MR patients from an international multi-center cohort:

- TEE videos standard views before and after procedure:
3D, **BIC**, and **LVOT**
- Tabular patient data including, degree of MR before and after TEER, past medical history, valve measurements, etc.



Bernal, Overview of Transesophageal Echocardiography for the Chest Physician, Chest, Volume 124, Issue 3, 2003, Pages 1081-1089,

AI models overview




- VideoMAE
- Artificial Neural Network (NN)
- CatBoost

Artificial Neural Network

Tabular Data

feature	feature	feature	feature	New
10	120	80	40	0:50:05
11	255	130	125	1:40:03
12	180	100	80	1:20:19
13	305	205	100	1:58:58
14	71	50	21	0:35:41
15	418	310	108	2:08:18
16	222	150	72	1:32:58


CatBoost



Credit to: Nadav Loeb


<https://arxiv.org/pdf/2203.12602.pdf>

Preliminary Results



Performance Metric	Average Value
Accuracy	74.76%
AUC	0.777
Sensitivity	88.33%
Specificity	60.0%
Positive Predictive Value	74.00%
F1-Score	78.61%

*** Using a cross-validation strategy, this involved training and testing five separate models on different 80%-20% splits of the data, results are the average of the five separate models.



תהנו מהמשך כנס המסתמים!

LEORPERL@GMAIL.COM

LEORPER@CLALIT.ORG.IL

054-9558228

